Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Short Interest Down 8.8% in January

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large decrease in short interest during the month of January. As of January 31st, there was short interest totalling 106,100 shares, a decrease of 8.8% from the January 15th total of 116,400 shares. Based on an average daily volume of 158,300 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.4% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “neutral” rating on shares of Bolt Biotherapeutics in a research report on Wednesday, November 13th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $3.50.

Bolt Biotherapeutics Price Performance

Shares of NASDAQ:BOLT opened at $0.49 on Wednesday. The firm has a market capitalization of $18.80 million, a PE ratio of -0.29 and a beta of 0.95. The company has a current ratio of 3.16, a quick ratio of 3.16 and a debt-to-equity ratio of 0.21. Bolt Biotherapeutics has a 1-year low of $0.46 and a 1-year high of $1.56. The business’s 50 day moving average is $0.52 and its 200-day moving average is $0.60.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Millennium Management LLC acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at $25,000. Squarepoint Ops LLC bought a new stake in Bolt Biotherapeutics in the fourth quarter valued at about $26,000. Velan Capital Investment Management LP acquired a new position in Bolt Biotherapeutics in the fourth quarter worth about $27,000. Citadel Advisors LLC acquired a new stake in Bolt Biotherapeutics during the fourth quarter valued at approximately $42,000. Finally, FMR LLC grew its stake in shares of Bolt Biotherapeutics by 33.2% in the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after purchasing an additional 28,773 shares during the period. 86.70% of the stock is owned by institutional investors.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.